Single-cell RNAseq Breast Cancer

NCT05807516 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-04-25

No results posted yet for this study

Summary

Molecular characterization of persistent tumor cells remaining after NAC and infiltrating immune cells, for example, M2 macrophages, could strongly contribute to identifying targeted therapeutic approaches for this disease.

Conditions

  • Breast Neoplasms

Interventions

OTHER

Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)

Combined both retrospective and prospective observational design

Sponsors & Collaborators

  • Regina Elena Cancer Institute

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2022-12-12
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05807516 on ClinicalTrials.gov